Evidence-based management of thrombosis in the antiphospholipid antibody syndrome
M Petri - Current rheumatology reports, 2003 - Springer
M Petri
Current rheumatology reports, 2003•SpringerRecommendations for the management of thrombosis in the antiphospholipid antibody
syndrome have been based largely on retrospective case series. Several clinical trials have
been recently published on the management of thrombosis in general. Two clinical trials
have specifically addressed thrombosis in antiphospholipid antibody syndrome, and one is
underway. These new clinical trials have challenged the previous dogma of a target
International Normalized Ratio of 3 to 4 (“high-intensity” warfarin).
syndrome have been based largely on retrospective case series. Several clinical trials have
been recently published on the management of thrombosis in general. Two clinical trials
have specifically addressed thrombosis in antiphospholipid antibody syndrome, and one is
underway. These new clinical trials have challenged the previous dogma of a target
International Normalized Ratio of 3 to 4 (“high-intensity” warfarin).
Abstract
Recommendations for the management of thrombosis in the antiphospholipid antibody syndrome have been based largely on retrospective case series. Several clinical trials have been recently published on the management of thrombosis in general. Two clinical trials have specifically addressed thrombosis in antiphospholipid antibody syndrome, and one is underway. These new clinical trials have challenged the previous dogma of a target International Normalized Ratio of 3 to 4 (“high-intensity” warfarin).
Springer